Evidence map›Paper›PMID 36922927›Full record

ArticleFrontiers in neuroscience2023

Severe pediatric acute encephalopathy syndromes related to SARS-CoV-2.

Hiroshi Sakuma, Jun-Ichi Takanashi, Kazuhiro Muramatsu, Hidehito Kondo, Takashi Shiihara, Motomasa Suzuki, Kazuo Okanari, Mariko Kasai, Osamu Mitani, Tomoyuki Nakazawa and 12 more

Open access · goldFull text read
In one paragraph

Article in Frontiers in neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Association ofFrontiers in neuroscience · 2023
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 18 institutions in 1 country.

Hiroshi SakumaDepartment of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Jun-Ichi TakanashiDepartment of Pediatrics and Pediatric Neurology, Tokyo Women's Medical University Yachiyo Medical Center, Tokyo, Japan.
Kazuhiro MuramatsuDepartment of Pediatrics, Jichi Medical University, Tochigi, Japan.
Hidehito KondoDepartment of Pediatrics, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Takashi ShiiharaDepartment of Neurology, Gunma Children's Medical Center, Gunma, Japan.
Motomasa SuzukiDepartment of Pediatric Neurology, Aichi Children's Health and Medical Center, Aichi, Japan.
Kazuo OkanariDepartment of Pediatrics, Oita Prefectural Hospital, Oita, Japan.
Mariko KasaiDepartment of Pediatrics, Saitama Citizens Medical Center, Saitama, Japan.
Osamu MitaniDepartment of Pediatrics, Fukuyama City Hospital, Hiroshima, Japan.
Tomoyuki NakazawaDepartment of Pediatrics, Tokyo Metropolitan Toshima Hospital, Tokyo, Japan.
Taku OmataDivision of Child Neurology, Chiba Children's Hospital, Chiba, Japan.
Konomi ShimodaDepartment of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
Yuichi AbeDivision of Neurology, National Center for Child Health and Development, Tokyo, Japan.
Yoshihiro MaegakiDivision of Child Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, Tottori, Japan.
Kei MurayamaCenter for Medical Genetics, Department of Metabolism, Chiba Children's Hospital, Chiba, Japan.
Yuka MurofushiDepartment of Pediatrics and Pediatric Neurology, Tokyo Women's Medical University Yachiyo Medical Center, Tokyo, Japan.
Hiroaki NagaseDepartment of Pediatrics, Kobe University Graduate School of Medicine, Hyōgo, Japan.
Akihisa OkumuraDepartment of Pediatrics, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Yasunari SakaiDepartment of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hiroko TadaDepartment of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Masashi MizuguchiDepartment of Pediatrics, National Rehabilitation Center for Children with Disabilities, Tokyo, Japan.
Japanese Pediatric Neuro-COVID-19 Study Group
Chiba Hospital · JPTokyo Women's Medical University · JPAichi Medical University · JPChibaken Saiseikai Narashino Hospital · JPCitizen (Japan) · JPFukuyama City Hospital · JPGunma Children's Medical Center · JPJichi Medical University · JPKobe University · JPKyoto first Red Cross hospital · JPKyushu University · JPNational Center For Child Health and Development · JPNational Rehabilitation Center for Persons with Disabilities · JPOita Prefectural Hospital · JPTokyo Metropolitan Institute of Medical Science · JPToshima Hospital · JPTottori University · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives: To clarify whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection cause acute encephalopathy in children and which are the most common syndromes that cause them and what are the outcomes. Methods: A nationwide web-based survey among all members of the Japanese Society of Child Neurology to identify pediatric patients aged < 18 years who developed acute encephalopathy in Japan between 1 January 2020 and 31 May 2022 associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by polymerase chain reaction or antigen tests using pharyngeal swabs. Acute encephalopathy was defined as acute onset of impaired consciousness lasting > 24 h or an altered mental state; neurological symptoms arising within 2 weeks of onset of COVID-19 or multisystem inflammatory syndrome in children (MIS-C)/pediatric inflammatory multisystem syndrome (PIMS); evidence of SARS-CoV-2 infection; and reasonable exclusion of other diseases. Patients were divided into the known clinico-radiological acute encephalopathy syndrome group and unexplained or unclassifiable acute encephalopathy group. Outcomes were assessed by pediatric cerebral performance category (PCPC) score at hospital discharge. Results: Of the 3,802 society members, 217 representing institutions responded, and 39 patients with suspected acute encephalopathy were reported, of which 31 met inclusion criteria. Of these patients, 14 were diagnosed with known clinico-radiological acute encephalopathy syndromes, with acute encephalopathy with biphasic seizures and late reduced diffusion (five patients) being the most common. Five developed acute encephalopathy associated with MIS-C/PIMS. Among 31 patients, 9 (29.0%) had severe sequelae or died (PCPC ≥ 4). Two of three patients with encephalopathy with acute fulminant cerebral edema and two with hemorrhagic shock and encephalopathy syndrome died. The PCPC scores were higher in the known clinico-radiological acute encephalopathy syndrome group than in the unexplained or unclassifiable acute encephalopathy group ( Discussion: Acute encephalopathy related to SARS-CoV-2 infection was demonstrated to be more severe than that caused by other viruses in Japan. Acute encephalopathy syndromes characterized by specific neuroradiological findings was associated with poor clinical outcomes.

Indexed as

acute encephalopathy syndromeacute encephalopathy with biphasic seizures and late reduced diffusion (AESD)clinico-radiological syndromeCOVID-19infection-triggered encephalopathy syndrome (ITES)outcomeSARS-CoV-2

Identifiers

PMID36922927
PMCPMC10008884
OpenAlexW4323317001

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read60
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.